Cardiotoxicity: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
( | {{Infobox medical condition | ||
| name = Cardiotoxicity | |||
{{ | | synonyms = | ||
| image = | |||
| caption = | |||
| pronounce = | |||
| specialty = [[Cardiology]], [[Oncology]] | |||
| symptoms = | |||
| complications = | |||
| onset = | |||
| duration = | |||
| types = | |||
| causes = Exposure to cardiotoxic agents | |||
| risks = | |||
| diagnosis = [[Echocardiogram]], [[Electrocardiogram]], [[Blood tests]] | |||
| differential = | |||
| prevention = | |||
| treatment = | |||
| medication = | |||
| prognosis = | |||
| frequency = | |||
| deaths = | |||
}} | |||
'''Cardiotoxicity''' refers to damage to the [[heart]] by harmful chemicals. As a significant side effect of certain medications, particularly [[chemotherapy]] agents and other drugs, it poses a serious risk for patients undergoing treatment for various conditions, including [[cancer]]. The understanding and management of cardiotoxicity are crucial in the fields of [[cardiology]] and [[oncology]]. | |||
==Causes== | |||
Cardiotoxicity can be caused by numerous agents including: | |||
* [[Chemotherapy]] drugs, such as anthracyclines (e.g., doxorubicin), and monoclonal antibodies (e.g., trastuzumab) | |||
* Radiation therapy, especially when the heart is within the radiation field | |||
* Some targeted therapies and other medications, such as tyrosine kinase inhibitors | |||
* Excessive exposure to certain environmental toxins | |||
==Mechanisms== | |||
The mechanisms of cardiotoxicity vary depending on the causative agent. For example, anthracyclines induce cardiotoxicity primarily through the generation of free radicals, which damage the cardiac muscle. Trastuzumab, on the other hand, can lead to heart dysfunction by interfering with HER2 signals, which are important for heart cell survival and repair. | |||
==Symptoms== | |||
Symptoms of cardiotoxicity may include: | |||
* [[Heart failure]] | |||
* [[Arrhythmia]]s | |||
* [[Cardiomyopathy]] | |||
* [[Ischemia]] | |||
==Diagnosis== | |||
Diagnosis of cardiotoxicity generally involves: | |||
* [[Echocardiogram]] to assess heart function | |||
* [[Electrocardiogram]] (ECG) to monitor heart rhythm | |||
* [[Blood tests]] to measure cardiac biomarkers | |||
==Prevention and Management== | |||
Prevention and management strategies for cardiotoxicity include: | |||
* Regular monitoring of heart function during and after treatment | |||
* Use of cardioprotective agents | |||
* Dose modification or discontinuation of the cardiotoxic drug | |||
==Prognosis== | |||
The prognosis for patients with cardiotoxicity varies based on the severity of the damage and the response to management strategies. Early detection and intervention are critical for improving outcomes. | |||
==See also== | |||
* [[Chemotherapy-induced cardiotoxicity]] | |||
* [[Radiation-induced heart disease]] | |||
* [[Drug-induced heart disease]] | |||
[[Category:Cardiology]] | |||
[[Category:Oncology]] | |||
[[Category:Toxicology]] | |||
{{medicine-stub}} | |||
Latest revision as of 20:22, 7 August 2024
| Cardiotoxicity | |
|---|---|
| Synonyms | |
| Pronounce | |
| Specialty | Cardiology, Oncology |
| Symptoms | |
| Complications | |
| Onset | |
| Duration | |
| Types | |
| Causes | Exposure to cardiotoxic agents |
| Risks | |
| Diagnosis | Echocardiogram, Electrocardiogram, Blood tests |
| Differential diagnosis | |
| Prevention | |
| Treatment | |
| Medication | |
| Prognosis | |
| Frequency | |
| Deaths | |
Cardiotoxicity refers to damage to the heart by harmful chemicals. As a significant side effect of certain medications, particularly chemotherapy agents and other drugs, it poses a serious risk for patients undergoing treatment for various conditions, including cancer. The understanding and management of cardiotoxicity are crucial in the fields of cardiology and oncology.
Causes[edit]
Cardiotoxicity can be caused by numerous agents including:
- Chemotherapy drugs, such as anthracyclines (e.g., doxorubicin), and monoclonal antibodies (e.g., trastuzumab)
- Radiation therapy, especially when the heart is within the radiation field
- Some targeted therapies and other medications, such as tyrosine kinase inhibitors
- Excessive exposure to certain environmental toxins
Mechanisms[edit]
The mechanisms of cardiotoxicity vary depending on the causative agent. For example, anthracyclines induce cardiotoxicity primarily through the generation of free radicals, which damage the cardiac muscle. Trastuzumab, on the other hand, can lead to heart dysfunction by interfering with HER2 signals, which are important for heart cell survival and repair.
Symptoms[edit]
Symptoms of cardiotoxicity may include:
Diagnosis[edit]
Diagnosis of cardiotoxicity generally involves:
- Echocardiogram to assess heart function
- Electrocardiogram (ECG) to monitor heart rhythm
- Blood tests to measure cardiac biomarkers
Prevention and Management[edit]
Prevention and management strategies for cardiotoxicity include:
- Regular monitoring of heart function during and after treatment
- Use of cardioprotective agents
- Dose modification or discontinuation of the cardiotoxic drug
Prognosis[edit]
The prognosis for patients with cardiotoxicity varies based on the severity of the damage and the response to management strategies. Early detection and intervention are critical for improving outcomes.
See also[edit]
